Coated, Impregnated, Or Colloidal Particulate (e.g., Microcapsule, Micro-sphere, Micro-aggregate, Macro-aggregate) Patents (Class 424/1.29)
-
Patent number: 8268358Abstract: Particles having a tap density of less than 0.4 g/cm3 include a hydrophobic amino acid or salt thereof and a therapeutic, prophylactic or diagnostic agent or any combination thereof. Preferred particles include a phospholipid, have a median geometric diameter between about 5 and about 30 microns and an aerodynamic diameter between about 1 and about 5 microns. The particles can be formed by spray-drying and are useful for delivery to the pulmonary system.Type: GrantFiled: January 20, 2011Date of Patent: September 18, 2012Assignee: Civitas Therapeutics, Inc.Inventors: Richard P. Batycky, Michael M. Lipp, Ralph W. Niven
-
Patent number: 8252339Abstract: A method for medical treatment was developed in which microspheres with novel properties are administered in a mammal. The microspheres are made using a novel process that results in microspheres with new combined properties of high density, low fracture, high swell capacity, rapid swell, and deformability following swell. These microspheres may be administered for void filling, tissue bulking, non-vasculature occlusion, body fluid absorption, and delivery of medications.Type: GrantFiled: April 5, 2007Date of Patent: August 28, 2012Assignees: E I du Pont de Nemours and CompanyInventors: Garret D. Figuly, Surbhi Mahajan, Rinaldo S. Schiffino, Sujata K. Bhatia, Elazer R. Edelman, Tarek Michael Shazly, Michael Jordan Feldstein
-
Publication number: 20120213698Abstract: The present invention relates to a novel composition and method for loading delivery systems such as liposome compositions with radionuclides useful in targeted diagnostic and/or therapy of target site, such as cancerous tissue and, in general, pathological conditions associated with leaky blood vessels. The composition and methods of the invention find particular use in diagnosing and imaging cancerous tissue and, in general, pathological conditions associated with leaky blood vessels in a subject. The present invention provides a new diagnostic tool for the utilization of positron emission tomography (PET) imaging technique. One specific aspect of the invention is directed to a method of producing nanoparticles with desired targeting properties for diagnostic and/or radio-therapeutic applications.Type: ApplicationFiled: July 16, 2010Publication date: August 23, 2012Inventors: Anncatrine Luisa Petersen, Palle Hedengran Rasmussen, Jonas Rosager Henriksen, Andreas Kjær, Thomas Lars Andresen
-
Publication number: 20120164065Abstract: A method for treating cancer, preventing cancer or delaying the progression of a cancer in an animal or human comprising the step of: administering to the animal or the human having a cancer a composition in an amount effective to treat cancer, prevent cancer or delay the progression of cancer in the animal or the human. The composition comprises a pharmaceutically acceptable excipient, and ascorbate which is joined to a carrier structure containing an anti-cancer active agent, said carrier structure being capable of releasing the anti-cancer agent in the presence of a reactive oxygen species.Type: ApplicationFiled: January 11, 2012Publication date: June 28, 2012Inventors: Anthony Manganaro, Karen Rockwell
-
Publication number: 20120134919Abstract: A method for formation of spherical particles of ion substituted calcium phosphate. The method is based on precipitation of particles from a buffered solution under static, stirring or hydrothermal conditions. Also, the use of the formed materials and the particles in itself.Type: ApplicationFiled: August 4, 2010Publication date: May 31, 2012Applicant: BIOMATCELL ABInventors: Hakan Engqvist, Wei Xia
-
Publication number: 20120134918Abstract: The invention provides a cancer therapeutic and imaging agent comprising a solution containing Gum Arabic coated 198Au nanoparticles. The Gum Arabic coated 198Au nanoparticles have been demonstrated experimentally shown to have a surprising efficacy for a single dose direct injection, reducing tumors in analog mice by 82% over a short period of time. The particles of the invention have a believed optimal size for therapy and imaging applications, and can be used as a theranostic agent in the treatment of needle accessible cancers. The invention also provides a method for forming Gum Arabic coated 198Au nanoparticles. A gold foil is irradiated to produce 198Au foil. The foil is dissolved to form radioactive gold salt. The salt is dried, and then reconstituted to form a 198Au nanoparticle precursor. The precursor is reduced with a reducing agent in an aqueous solution including Gum Arabic to form Gum Arabic coated 198Au nanoparticles.Type: ApplicationFiled: November 10, 2011Publication date: May 31, 2012Applicant: The Curators of the University of MissouriInventors: Kattesh V. Katti, Raghuraman Kannan, Cathy S. Cutler
-
Publication number: 20120123189Abstract: An oncology therapy method comprises implanting a radioactive seed (10, 20, 30, 40, 50) in an oncology subject (S). In some embodiments the radioactive seed comprises a radioactive material (12, 32, 33, 42) including at least one radioisotope disposed in a biodegradable host (14, 24, 25, 44) configured to biodegrade over a therapy time period when implanted in the oncology subject. In some embodiments the radioactive seed is implanted in soft tissue of an oncology subject (S), and the radioactive seed comprises a radioactive material (12, 32, 33, 42) including at least one radioisotope disposed in a host material (14, 24, 25, 44) having softness comparable with or softer than the soft tissue into which the radioactive seed is implanted.Type: ApplicationFiled: July 6, 2010Publication date: May 17, 2012Applicant: KONINKLIJKE PHILIPS ELECTRONICS N.V.Inventors: Carolina Ribbing, Michael Overdick
-
Publication number: 20120093718Abstract: Formulations of neutral retinoids, in particular fenretinide (HPR) in the form of lipid nanoparticles, solid dipersions and emulsions are disclosed. These compositions are used to treat diseases that are amenable to treatment by HPR, such as neoplastic diseases by achieving higher and more prolonged concentrations of HPR in the subject. The key steps for preparing lipid nanovesicles of HPR include mixing and sonication, sterile filtration, without or without lyophilization for long-term stable storage, and employ processes and materials that are scalable from the laboratory to the manufacturing level. The formulation are suitable for injection into human or animal patients without causing allergic or hypersensitivity responses by avoiding chemical surfactants and animal sources of phospholipids in their manufacture.Type: ApplicationFiled: March 29, 2007Publication date: April 19, 2012Applicants: SCITECH DEVELOPMENT, LLC, WAYNE STATE UNIVERSITYInventors: Ralph E. Parchment, Bhaskara R. Jasti, Ramesh R. Boinpally, Stephen E. Rose, Earle T. Holsapple
-
Patent number: 8158106Abstract: Surface coatings including microparticles immobilized in a matrix of polymeric material on a substrate are described. The microparticles can also include an agent which can be useful for various applications, such as medical applications. This invention relates to the field of surface coatings for use in various applications. More particularly, the invention relates to surface coating useful for drug delivery, imaging and other uses of microparticles immobilized via a polymeric matrix.Type: GrantFiled: September 30, 2002Date of Patent: April 17, 2012Assignee: Surmodics, Inc.Inventors: Patrick E. Guire, Kristin S. Taton, John V. Wall
-
Patent number: 8147805Abstract: Compositions and methods for dual imaging and for dual chemotherapy and radiotherapy are disclosed. More particularly, the invention concerns compounds comprising the structure X1—Y—X2, wherein Y comprises two or more carbohydrate residues covalently attached to one another, X1 and X2 are diagnostic or therapeutic moieties covalently attached to Y, provided that when Y does not comprise a glucosamine residue, X1 and X2 are diagnostic moieties. The present invention also concerns methods of synthesis of these compounds, application of such compounds for dual imaging and treatment of hyperproliferative disease, and kits for preparing a radiolabeled therapeutic or diagnostic compound.Type: GrantFiled: January 5, 2006Date of Patent: April 3, 2012Assignee: The Board of Regents of The University of T exas SystemInventors: David Yang, Dongfang Yu, Mithu Chanda, Ali Azhdarinia, Changsok Oh, E. Edmund Kim
-
Publication number: 20120076723Abstract: The invention relates to the treatment of cancer. In particular the invention relates to an internal therapeutic product comprising: (i) an anti-cancer component selected from one or both of: a radionucleotide, a cytotoxic drug; and (ii) a silicon component selected from one or more of: resorbable silicon, biocompatible silicon, bioactive silicon, porous silicon, polycrystalline silicon, amorphous silicon, and bulk crystalline silicon, the internal therapeutic product being for the treatment of cancer.Type: ApplicationFiled: December 8, 2011Publication date: March 29, 2012Applicant: pSiMedica LimitedInventors: Roger ASTON, Leigh T. Canham
-
Patent number: 8142758Abstract: The present invention provides Hydroxyapatite (HA) incorporating an alpha-emitting radionuclide or an in vivo generator for an alpha-emitting radionuclide. The invention further provides methods for the formation of such HA, pharmaceutical compositions comprising the HA and methods of medical treatment of cancerous or noncancerous disease including administering the HA or compositions thereof.Type: GrantFiled: February 18, 2005Date of Patent: March 27, 2012Assignee: Algeta ASInventors: Roy H. Larsen, Gro Salberg
-
Publication number: 20120070371Abstract: This invention relates to low density radioactive magnesium-aluminum-silicate (MAS) microparticles that contain either samarium-yttrium, samarium, or lutetium as medical isotopes for radiotherapy and/or radioimaging.Type: ApplicationFiled: September 16, 2010Publication date: March 22, 2012Inventors: Delbert E. Day, Yiyong He
-
Publication number: 20120058048Abstract: The present invention relates enhanced targeting of drug delivery vehicles to vascular endothelial cellsType: ApplicationFiled: September 7, 2010Publication date: March 8, 2012Inventor: William Herman
-
Publication number: 20120052006Abstract: The present disclosure is directed generally to gold/lanthanide nanoparticle conjugates, such as gold/gadolinium nanoparticle conjugates, nanoparticle conjugates including polymers, nanoparticle conjugates conjugated to targeting agents and therapeutic agents, and their use in targeting, treating, and/or imaging disease states in a patient.Type: ApplicationFiled: February 17, 2010Publication date: March 1, 2012Applicant: COLORADO SCHOOL OF MINESInventors: Stephen G. Boyes, Misty D. Rowe
-
Publication number: 20120020879Abstract: Provided herein is a process for production of a metal nanoparticle, the process comprising providing a first solution containing a protein nanocage complex comprising a hydrophobic metal core and an ion-transport mechanism, providing a second solution containing a preselected anionic agent, combining the first and second solutions into a third combined solution, and applying an external method to the third combined solution to manipulate the metal core's redox state, in which reduction of the metal core causes the preselected anionic agent to be imported and incorporated into the metal core. Also provided herein is a composition from the process and a method of use.Type: ApplicationFiled: July 22, 2011Publication date: January 26, 2012Applicant: Brigham Young UniversityInventor: Richard K. Watt
-
Publication number: 20110286915Abstract: The present invention provides a nanocarrier having an interior and an exterior, the nanocarrier comprising at least one conjugate, wherein each conjugate includes a polyethylene glycol (PEG) polymer. Each conjugate also includes at least two amphiphilic compounds having both a hydrophilic face and a hydrophobic face. In addition, each conjugate includes an oligomer, wherein at least 2 of the amphiphilic compounds are covalently attached to the oligomer which is covalently attached to the PEG. The nanocarrier is such that each conjugate self-assembles in an aqueous solvent to form the nanocarrier such that a hydrophobic pocket is formed in the interior of the nanocarrier by the orientation of the hydrophobic face of each amphiphilic compound towards each other, and wherein the PEG of each conjugate self-assembles on the exterior of the nanocarrier.Type: ApplicationFiled: September 22, 2009Publication date: November 24, 2011Applicant: The Regents of the University of CaliforniaInventors: Kit S. Lam, Juntao Luo
-
Patent number: 8062673Abstract: A method for embolization treatment was developed in which microspheres with novel properties are administered in a mammal. The microspheres are made using a novel process that results in microspheres with new combined properties of high density, low fracture, high swell capacity, rapid swell, and deformability following swell. These microspheres form occlusions with high durability, withstanding over 100 mm Hg (13.3 kPa) of pressure.Type: GrantFiled: April 5, 2007Date of Patent: November 22, 2011Assignee: E I Du Pont de Nemours and CompanyInventors: Garret D. Figuly, Surbhi Mahajan, Rinaldo S. Schiffino, Michael Jordan Feldstein, Tarek Michael Shazly, Elazer R. Edelman
-
Patent number: 8029985Abstract: A method for assaying a biological sample includes forming sensitized microcapsules filled with unique oligomarkers, capturing sensitized microcapsules in the presence of analytes, releasing oligomarkers from microcapsules and detecting and measuring oligomarkers to detect and quantify presence of analyte in biological sample. Using encapsulated oligomarkers provides for an amplified high sensitivity assay and using plurality of oligomarker types provides for a multiplexed assay.Type: GrantFiled: August 30, 2005Date of Patent: October 4, 2011Assignee: Vybion, Inc.Inventors: Leo B Kriksunov, Geoffrey Wheelock, Lee A Henderson
-
Publication number: 20110200526Abstract: A system combines hyperthermia and radiation treatments in a single treatment modality by using a radioactive seed having magnetic properties.Type: ApplicationFiled: October 28, 2009Publication date: August 18, 2011Applicant: UNIVERSITY OF TOLEDOInventors: E. Ishmael Parsai, John J. Feldmeier
-
Publication number: 20110190566Abstract: The present invention relates to polymer microgel beads having a polymeric matrix with nanomagnetic particles dispersed substantially uniformly therethrough, wherein a steric stabiliser is associated with the particles, the steric stabiliser being a polymeric material that (i) does not form part of the polymeric matrix of the beads, and (ii) comprises a steric stabilising polymeric segment and an anchoring polymeric segment, wherein the steric stabilising polymeric segment is different from the anchoring polymeric segment, and wherein the anchoring polymeric segment has an affinity toward the surface of the nanomagnetic particles and secures the stabiliser to the particles.Type: ApplicationFiled: May 15, 2009Publication date: August 4, 2011Applicant: University Of SydneyInventors: Brian Stanley Hawkett, Nirmesh Jain
-
Publication number: 20110165069Abstract: The present invention relates to a method for preparing a radiolabeled macromolecule, the method comprising contacting a macromolecule with a carbon encapsulated nanoparticle composite having a radioactive particulate core in an aqueous medium comprising a pH selected to promote short-range attractive forces between the nanoparticles and the macromolecule by attenuating repulsive electrostatic forces.Type: ApplicationFiled: April 23, 2009Publication date: July 7, 2011Applicant: The Australian National UniversityInventors: Ross Wentworth Stephens, Timothy John Senden, David Wallace King
-
Publication number: 20110165070Abstract: The present invention relates to a method for preparing a radiolabeled synthetic polymer, the method comprising contacting a synthetic polymer with a carbon encapsulated nanoparticle composite having a radioactive particulate core in an aqueous medium comprising an electrolyte concentration or pH selected to promote short-range attractive forces between the nanoparticles and the synthetic polymer by attenuating long-range electrostatic repulsive forces.Type: ApplicationFiled: April 23, 2009Publication date: July 7, 2011Applicant: The Australian National UniversityInventors: Ross Wentworth Stephens, Timothy John Senden, David Wallace King
-
Publication number: 20110150938Abstract: The present invention concerns size- and shape-controlled, colloidal superparticles (SPs) and methods for synthesizing the same. Ligand-functionalized nanoparticles such as nonpolar-solvent-dispersible nanoparticles, are used, and the solvophobic interactions can be controlled. Advantageously, supercrystalline SPs having a superlattice structure, such as a face-centered cubic structure, can be produced. Further, the methods of the invention can provide SPs that self-assemble and are monodisperse. The SPs can be doped with organic dyes and further assembled into more complex structures.Type: ApplicationFiled: August 15, 2008Publication date: June 23, 2011Applicant: University of Florida Research Foundation, Inc.Inventors: Y. Charles Cao, Jiaqi Zhuang, Huimeng Wu, Yongan Yang
-
Patent number: 7959900Abstract: Timed-bioresorbable particulates, particularly microspheres or fibers, may be used as a vehicle for delivery of radioisotopes, such as Y-90 and Pd-103 for localized radiotherapy, or as an embolic device. These particulates may also be embedded in polymers, or dispersed in injectable gels or other injectable media for the treatment of various cancers. The benefit of bioresorption, the ability to control the ratio of radioisotopes in the particulate, especially the gamma and beta ratios such as In-111/Y-90 ratio in a particulate, and the benefit of non-conductive implants are disclosed.Type: GrantFiled: March 7, 2005Date of Patent: June 14, 2011Assignee: XL Sci-Tech, Inc.Inventors: Yongren Benjamin Peng, Xingye Cherry Lei
-
Publication number: 20110129413Abstract: Non-aggregating resorbable calcium phosphosilicate nanoparticles (CPNPs) are bioconjugated to targeting molecules that are specific for particular cells. The CPNPs are stable particles at normal physiological pH. Chemotherapy and imaging agents may be integrally formed with the CPNPs so that they are compartmentalized within the CPNPs. In this manner, the agents are protected from interaction with the environment at normal physiological pH. However, once the CPNPs have been taken up, at intracellular pH, the CPNPs dissolve releasing the agent. Thus, chemotherapeutic or imaging agents are delivered to specific cells and permit the treatment and/or imaging of those cells. Use of the bioconjugated CPNPs both limits the amount of systemic exposure to the agent and delivers a higher concentration of the agent to the cell. The methods and principals of bioconjugating CPNPs are taught by examples of bioconjugation of targeting molecules for breast cancer, pancreatic cancer, and leukemia.Type: ApplicationFiled: November 8, 2010Publication date: June 2, 2011Inventors: Thomas T. Morgan, Brian M. Barth, James H. Adair, Rahul Sharma, Mark Kester, Sriram S. Shanmugavelandy, Jill P. Smith, Erhan I. Altinoglu, Gail L. Matters, James M. Kaiser, Christopher McGovern
-
Publication number: 20110123439Abstract: The present invention relates a dual-modality PET (positron emission tomography)/MRI (magnetic resonance imaging) contrast agent, a hybrid nanoparticle comprising: (a) a magnetic signal generating core; (b) a water-soluble multi-functional ligand coated on the signal generating core; and (c) a positron emitting factor linked to the water-soluble multi-functional ligand. The contrast agent of the present invention is the dual-modality contrast agent enabling to perform PET and MR imaging and can effectively obtain images having the merits of PET (excellent sensitivity and high temporal resolution) and MR (high spatial resolution and anatomical information) imaging. The contrast agent of the present invention is very useful for non-invasive and highly sensitive real-time fault-free imaging of various biological events such as cell migration, diagnosis of various diseases (e.g., cancer diagnosis) and drug delivery.Type: ApplicationFiled: May 8, 2009Publication date: May 26, 2011Applicants: Industry-Academic Cooperation Foundation, Yonsei University, Kyungpook National University Industry-Academic Cooperation FoundationInventors: Jin Woo Cheon, Jin-Sil Choi, Jeongsoo Yoo, Jeong Chan Park, Yongmin Chang
-
Patent number: 7947309Abstract: Compositions are provided which include hyaluronic acid derivatives in combination with vaccine antigens, and optionally adjuvants, for mucosal delivery. Also provided are methods of making the compositions, as well as methods of immunization using the same.Type: GrantFiled: November 10, 2009Date of Patent: May 24, 2011Assignee: Fidia Farmaceutici S.p.AInventors: Derek O'Hagan, Alessandra Pavesio
-
Patent number: 7942957Abstract: The present invention relates to an antimicrobial composition having antibacterial and antifungal properties and to an air filter manufactured using the composition. The filter of the present invention, comprising a filtration media treated with the antimicrobial composition having antibacterial and antifungal properties, has excellent antibacterial and antifungal properties, and thus can prevent the bacteria and fungi filtered by the filter from propagating in the filter.Type: GrantFiled: January 24, 2007Date of Patent: May 17, 2011Assignee: 3M Innovative Properties CompanyInventors: Jun Seok Lee, Sunghak Hwang, Seongju Kim
-
Patent number: 7888119Abstract: A biocompatible composite includes a solid biocompatible material and a plurality of living human progenitor or living stem cells attached thereto. The biocomposite provides a stable interface with endogenous tissue and the implanted composition resulting in accelerated repair to damaged bones and tissues.Type: GrantFiled: October 16, 2006Date of Patent: February 15, 2011Assignee: University of Central Florida Research Foundation, Inc.Inventors: Kiminobu Sugaya, Stephanie Merchant, Sudipta Seal, Petya Georgieva, Manny Vrotsos
-
Publication number: 20110027172Abstract: The present invention provides a drug delivery system for delivery of an agent and a radiopharmaceutical agent. The drug delivery system may specifically target an organ, tissue, cells, extracellular matrix, or intracellular compartment. Typically, the drug delivery system is a particle. Pharmaceutical compositions comprising the inventive particles are also provided. The present invention provides methods of preparing and using the inventive particles and pharmaceutical compositions. The inventive particles are useful in treating and diagnosing a variety of diseases including cancer. The inventive particles are also useful in tracking particles in vivo.Type: ApplicationFiled: December 10, 2008Publication date: February 3, 2011Inventors: Zhuang Wang, Omid C. Farokhzad, Liangfang Zhang, Aleksandar Filip Radovic-Moreno, Frank X. Gu, Robert S. Langer
-
Publication number: 20100290983Abstract: The present disclosure is directed to surface-modified particles and to methods of making and using the same.Type: ApplicationFiled: May 15, 2009Publication date: November 18, 2010Applicants: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE S.A.Inventors: Barrett Rabinow, Shawn F. Bairstow, Mahesh V. Chaubal, Sarah Lee, Jane Werling
-
Patent number: 7824660Abstract: The present invention provides a novel approach to cancer therapy and diagnostics that utilizes nanotubes and other similar nanostructures as both an indirect source of radiation therapy (BNCT), and as delivery vehicles for other types of radio- and chemo-therapeutic materials, as well as imaging agents for diagnostic purposes.Type: GrantFiled: April 30, 2008Date of Patent: November 2, 2010Inventors: Dan A. Buzatu, Jon G. Wilkes, Dwight Miller, Jerry A. Darsey, Tom Heinze, Alex Birls, Richard Beger
-
Publication number: 20100266491Abstract: The present invention provides a drug delivery system for targeted delivery of therapeutic agent-containing particles to tissues, cells, and intracellular compartments. The invention provides targeted particles comprising a particle, one or more targeting moieties, and one or more therapeutic agents to be delivered and pharmaceutical compositions comprising inventive targeted particles. The present invention provides methods of designing, manufacturing, and using inventive targeted particles and pharmaceutical compositions thereof.Type: ApplicationFiled: September 26, 2008Publication date: October 21, 2010Applicants: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventors: Omid C. FAROKHZAD, Jianjun CHENG, Benjamin A. TEPLY, Robert S. LANGER, Stephen E. ZALE
-
Patent number: 7811550Abstract: This invention comprises nanoparticles for use with biosensors. The nanoparticles have core/shell architecture. The nanoparticles can be detected by two means, magnetic and optical by virtue of the nanoparticles magnetic core and fluorescent semiconductor shell. Methods of making the nanoparticles and their composition are described.Type: GrantFiled: May 19, 2006Date of Patent: October 12, 2010Assignee: The United States of America as represented by the Secretary of the NavyInventors: Everett E. Carpenter, Vincent Carpenter
-
Publication number: 20100254897Abstract: A contrast marker having a casing and a novel MRI contrast agent comprising metal complexes disposed around, within, or abuting the casing is provided. Such contrast markers may be placed in a strand, with or without a therapy seed, to produce a seeded strand useful for imaging and in connection with brachytherapy.Type: ApplicationFiled: July 11, 2008Publication date: October 7, 2010Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Steven J. Frank, Karen Martirosyan
-
Patent number: 7794755Abstract: A process for producing microspheres was developed that provides microspheres with new combined properties of high density, low fracture, high swell capacity, rapid swell, and deformability following swell. The process is reliable and high yielding, and makes use of a low temperature azo initiator and a small molecule chlorinated solvent as the organic phase. The microsphere preparation made using the process is particularly useful in medical treatments such as embolization.Type: GrantFiled: April 5, 2007Date of Patent: September 14, 2010Assignee: E.I. du Pont de Nemours and CompanyInventors: Garret D. Figuly, Surbhi Mahajan, Rinaldo S. Schiffino
-
Publication number: 20100226853Abstract: Provided herein are [18F]-labeled compounds having a chemical structure: R1 is 18F, 1-piperazinyl-4-CH2CH2—18F or 1-piperazinyl-4-CH2CH2OCH2CH2—18F, R2 is CH3 or 18F and R3 is Cl or 18F, such that only one of R1, R2 and R3 comprise an 18F. Also provided are methods for in vivo imaging using the [18F]-labeled compounds, particularly methods of imaging utilizing positron emission tomography. These methods are effective for diagnosing a pathophysiological condition susceptible to treatment with kinase inhibitor(s) in a subject, or for determining whether a cancer in a subject that is susceptible to being treated with a kinase inhibitor has developed resistance or increased sensitivity to the same and for maximizing tumor response to akinase inhibitor with minimal toxicity to the subject.Type: ApplicationFiled: April 5, 2010Publication date: September 9, 2010Inventors: Darren R. Veach, Nagavara Kishore Pillarsetty, Steven M. Larson, Elmer B. Santos, Mohammad Namavari
-
Publication number: 20100183504Abstract: In certain embodiments this invention provides a nanoparticle-based technology platform for multimodal in vivo imaging and therapy. The nanoparticle-based probes detects diseased cells by MRI, PET or deep tissue Near Infrared (NIR) imaging, and are capable of detecting diseased cells with greater sensitivity than is possible with existing technologies. The probes also target molecules that localize to normal or diseased cells, and initiates apoptosis of diseased cells.Type: ApplicationFiled: June 13, 2008Publication date: July 22, 2010Inventor: Fanqing Frank Chen
-
Publication number: 20100178244Abstract: A composition and method for targeted use of radionuclide therapy for the treatment of cancer and cancerous tumors, atherosclerotic plaques, joints and other targeted sites. Microparticles, microbubbles, or nanoparticles deliver therapeutic doses of radiation, included radiation from alpha emitting radionuclides, to sites in a patient. The delivery may be targeted by targeting agents linked to the microparticles, microbubbles, or nanoparticles or by the external application of energy, or both.Type: ApplicationFiled: January 13, 2009Publication date: July 15, 2010Inventors: Morton F. Arnsdorf, Jenny Whitlock
-
Publication number: 20100178245Abstract: A composition and method for targeted use of radionuclide therapy for the treatment of cancer and cancerous tumors, atherosclerotic plaques, joints and other targeted sites. Microparticles, microbubbles, or nanoparticles deliver therapeutic doses of radiation, included radiation from alpha emitting radionuclides, to sites in a patient. The delivery may be targeted by targeting agents linked to the microparticles, microbubbles, or nanoparticles or by the external application of energy, or both.Type: ApplicationFiled: April 16, 2009Publication date: July 15, 2010Inventors: Morton F. Arnsdorf, Jenny L. Whitlock
-
Publication number: 20100172831Abstract: A protein-modified droplet includes a droplet having a liquid material, and a protein structure formed to at least partially enclose the droplet. The protein structure includes a plurality of protein molecules having an affinity to at least a region of the droplet during formation of the protein structure, and the droplet has a maximum dimension of at least about 1 nm and less than about 1000 nm. A composition includes a plurality of protein-modified droplets dispersed in an aqueous solution.Type: ApplicationFiled: April 18, 2008Publication date: July 8, 2010Inventors: Thomas G. Mason, Connie B. Chang
-
Publication number: 20100166651Abstract: The present invention provides a radiotherapeutic composition comprising a high specific activity tin-117m source of radiotherapeutic atomic electrons and a delivery vehicle, e.g., a chelator or nanosphere or microsphere effective to contain tin-117m therein. The present invention also provides a targeting moiety linked to the delivery vehicle. Further provided are methods of treating a bone-associated pathophysiological condition or imaging the same using the high specific activity radiotherapeutic compositions.Type: ApplicationFiled: December 19, 2006Publication date: July 1, 2010Inventor: Marlene OLIVER
-
Publication number: 20100158800Abstract: The present invention relates to novel drug depot implant designs for optimal delivery of therapeutic agents to subjects. The invention provides a method for alleviating pain associated with neuromuscular or skeletal injury or inflammation by targeted delivery of one or more therapeutic agents to inhibit the inflammatory response which ultimately causes acute or chronic pain. Controlled and directed delivery can be provided by drug depot implants, comprising therapeutic agents, specifically designed to deliver the therapeutic agent to the desired location by facilitating their implantation, minimizing their migration from the desired tissue location, and without disrupting normal joint and soft tissue movement.Type: ApplicationFiled: March 3, 2010Publication date: June 24, 2010Applicant: WARSAW ORTHOPEDIC, INC.Inventor: William F. Mckay
-
Publication number: 20100150828Abstract: Methods of preparing a composition comprising non-ionic, radioactive gold nanoparticles (R-GNPs) are disclosed. The method comprises: a) providing a solution comprising gold (Au-197) ions; and b) exposing the solution to neutron irradiation to generate a composition comprising non-ionic R-GNPs. Alternatively, the method comprises: a) providing a solution that comprises a composition comprising gold (Au-197) nanoparticles (GNPs); and b) exposing the GNP solution to neutron irradiation to generate a composition comprising non-ionic R-GNPs. Compositions that comprises non-ionic R-GNPs encapsulated within and/or anchored to MSNs, and methods of making the same are also disclosed.Type: ApplicationFiled: December 14, 2009Publication date: June 17, 2010Applicants: NATIONAL HEALTH RESEARCH INSTITUTES, National Tsing Hua UniversityInventors: Jen-Kun CHEN, Jinn-Jer Peir, Chung-Shi Yang, Mei-Ya Wang, Chih-Hui Liu, Fong-In Chou, Mo-Hsiung Yang, Mei-Hui Shih
-
Publication number: 20100143243Abstract: Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue.Type: ApplicationFiled: September 15, 2009Publication date: June 10, 2010Inventors: Edward S. Boyden, Daniel B. Cook, Roderick A. Hyde, Eric C. Leuthardt, Nathan P. Myhrvold, Elizabeth A. Sweeney, Lowell L. Wood, JR.
-
Publication number: 20100111846Abstract: Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue.Type: ApplicationFiled: March 20, 2009Publication date: May 6, 2010Inventors: Edward S. Boyden, Daniel B. Cook, Roderick A. Hyde, Eric C. Leuthardt, Nathan P. Myhrvold, Elizabeth A. Sweeney, Lowell L. Wood, JR.
-
Publication number: 20100111848Abstract: Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue.Type: ApplicationFiled: March 27, 2009Publication date: May 6, 2010Inventors: Edward S. Boyden, Daniel B. Cook, Roderick A. Hyde, Eric C. Leuthardt, Nathan P. Myhrvold, Elizabeth A. Sweeney, Lowell L. Wood, JR.
-
Publication number: 20100111842Abstract: Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue.Type: ApplicationFiled: October 31, 2008Publication date: May 6, 2010Inventors: Edward S. Boyden, Roderick A. Hyde, Eric C. Leuthardt, Nathan P. Myhrvold, Elizabeth A. Sweeney, Lowell L. Wood, JR.
-
Publication number: 20100111843Abstract: Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue.Type: ApplicationFiled: October 31, 2008Publication date: May 6, 2010Inventors: Edward S. Boyden, Roderick A. Hyde, Eric C. Leuthardt, Nathan P. Myhrvold, Elizabeth A. Sweeney, Lowell L. Wood, JR.